198 related articles for article (PubMed ID: 20676947)
41. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.
Koutsonanos DG; Vassilieva EV; Stavropoulou A; Zarnitsyn VG; Esser ES; Taherbhai MT; Prausnitz MR; Compans RW; Skountzou I
Sci Rep; 2012; 2():357. PubMed ID: 22500210
[TBL] [Abstract][Full Text] [Related]
42. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
[TBL] [Abstract][Full Text] [Related]
43. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses.
Fernando GJ; Zhang J; Ng HI; Haigh OL; Yukiko SR; Kendall MA
J Control Release; 2016 Sep; 237():35-41. PubMed ID: 27381247
[TBL] [Abstract][Full Text] [Related]
44. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
[TBL] [Abstract][Full Text] [Related]
45. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.
Vrdoljak A; Allen EA; Ferrara F; Temperton NJ; Crean AM; Moore AC
J Control Release; 2016 Mar; 225():192-204. PubMed ID: 26774221
[TBL] [Abstract][Full Text] [Related]
46. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
Weldon WC; Martin MP; Zarnitsyn V; Wang B; Koutsonanos D; Skountzou I; Prausnitz MR; Compans RW
Clin Vaccine Immunol; 2011 Apr; 18(4):647-54. PubMed ID: 21288996
[TBL] [Abstract][Full Text] [Related]
47. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
48. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
49. Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles.
Braz Gomes K; Vijayanand S; Bagwe P; Menon I; Kale A; Patil S; Kang SM; Uddin MN; D'Souza MJ
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445784
[TBL] [Abstract][Full Text] [Related]
50. Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.
Choi HJ; Song JM; Bondy BJ; Compans RW; Kang SM; Prausnitz MR
PLoS One; 2015; 10(7):e0134431. PubMed ID: 26230936
[TBL] [Abstract][Full Text] [Related]
51. C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin.
Shin JH; Lee JH; Jeong SD; Noh JY; Lee HW; Song CS; Kim YC
Drug Deliv Transl Res; 2020 Jun; 10(3):815-825. PubMed ID: 32141036
[TBL] [Abstract][Full Text] [Related]
52. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
53. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
54. Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine.
Choi IJ; Kang A; Ahn MH; Jun H; Baek SK; Park JH; Na W; Choi SO
J Control Release; 2018 Sep; 286():460-466. PubMed ID: 30102940
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.
Gwon YD; Kim S; Cho Y; Heo Y; Cho H; Park K; Lee HJ; Choi J; Poo H; Kim YB
PLoS One; 2016; 11(5):e0154824. PubMed ID: 27149064
[TBL] [Abstract][Full Text] [Related]
56. Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch.
Zhu W; Li S; Wang C; Yu G; Prausnitz MR; Wang BZ
Front Immunol; 2018; 9():1705. PubMed ID: 30105019
[TBL] [Abstract][Full Text] [Related]
57. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
Crevar CJ; Carter DM; Lee KY; Ross TM
Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
[TBL] [Abstract][Full Text] [Related]
58. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
59. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
[TBL] [Abstract][Full Text] [Related]
60. Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.
Valero-Pacheco N; Pérez-Toledo M; Villasís-Keever MÁ; Núñez-Valencia A; Boscó-Gárate I; Lozano-Dubernard B; Lara-Puente H; Espitia C; Alpuche-Aranda C; Bonifaz LC; Arriaga-Pizano L; Pastelin-Palacios R; Isibasi A; López-Macías C
PLoS One; 2016; 11(2):e0150146. PubMed ID: 26919288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
